Atea Pharmaceuticals
↗Boston, Massachusetts, United States
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company founded in 2012 that discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. The company leverages a proprietary nucleos(t)ide prodrug platform to develop direct-acting antivirals (DAAs) targeting single-stranded RNA viruses with unmet medical needs. Atea's lead program is a fixed-dose combination regimen of bemnifosbuvir (NS5B inhibitor) and ruzasvir (NS5A inhibitor) currently in Phase 3 global clinical development for hepatitis C virus (HCV) treatment, with two pivotal trials (C-BEYOND in North America and C-FORWARD internationally) expected to deliver topline results in 2026. The company is also expanding its pipeline with AT-587, a first-in-class candidate for hepatitis E virus (HEV) treatment entering Phase 1 development in 2026.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Pharmaceuticals and Biotechnology
Sub-Industry:Clinical-stage biopharmaceutical (antivirals)
SIZE & FINANCIALS
Employees:51-200
Revenue:$0M-$50M
Founded:2012
Ownership:public
Status:operating
FUNDING
Stage:Public
Total Raised:~$500M+
Investors:Bain Capital Life Sciences, Adage Capital, Aju IB Investment, Ally Bridge Group, Cormorant Asset Management, Morningside Ventures, Omega Funds, Perceptive Advisors, RA Capital, Redmile Group, RMI Partners, Rock Springs Capital, Sectoral Asset Management, BlackRock, Vanguard Group, Fidelity Management & Research Company
STOCK
Exchange:NASDAQ
Ticker:AVIR
Market Cap:$482.8M
PIPELINE
Stage:Phase 3 (HCV), Phase 1 planned (HEV)
Lead Drug Stage:Phase 3
Modalities:Nucleotide prodrugs, Small molecule antivirals
Active Trials:2
Trial Phases:Phase 3: 2
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
Competitors:Gilead Sciences (Harvoni, Epclusa), AbbVie (Mavyret), Merck, Johnson & Johnson, Bristol-Myers Squibb, Roche
LEADERSHIP
Key Executives:
Jean-Pierre Sommadossi, Ph.D. - Chairman, Chief Executive Officer & President
Andrea J. Corcoran - Chief Financial Officer, Executive Vice President of Legal & Secretary
Wayne Foster, CPA - Executive Vice President of Finance & Chief Accounting Officer
Janet Hammond - Chief Development Officer
Maria Horga - Chief Medical Officer
Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications
Scientific Founders:Jean-Pierre Sommadossi, Ph.D.
Board Members:Jean-Pierre Sommadossi (Chairman & CEO), Jerome Adams (Former U.S. Surgeon General), Franklin Berger (Founding & Managing Director, FMB Research), Howard H. Berman (Executive Chairman, Coya Therapeutics), Barbara Duncan (Former CFO, Intercept Pharmaceuticals)
LINKS
Website:ateapharma.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Atea Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Atea Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.